Modified Second Haplo-transplantation for Graft Failure

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jul 16, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for patients who experience graft failure after their first stem cell transplant. Graft failure is a serious condition where the transplanted cells do not work properly, and a second transplant may be needed. The researchers are testing a modified treatment plan that they believe will help patients recover better and faster after the second transplant, especially when it comes to their platelet levels, which are important for blood clotting.

To participate in this trial, patients must be at least 14 years old and have specific blood cancers like leukemia or lymphoma. They should have had their first transplant less than six months ago and must be experiencing graft failure. However, patients with active infections, certain organ problems, or who are unable to cooperate with the study will not be eligible. Those who join the study can expect to receive the modified treatment and be closely monitored for safety and effectiveness. Overall, this trial aims to improve outcomes for patients facing this challenging situation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.Primary disease: hematological malignancies(AML, CML, MDS, lymphoma, etc.); 2.Graft failure after first allogeneic stem cell transplantation; 3.Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years.
• Exclusion Criteria:
• • 1. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\<50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\>2; 5. Expected life time\<30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,